Simcere Reports Positive Phase IV Interim Results For Lung Cancer Drug Endu
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Simcere Pharmaceutical reported positive interim results for Phase IV clinical trials of its recombinant human endostatin lung cancer drug Endu, the company announced Sept. 3
You may also be interested in...
Magnitude 7.9 Quake Cut into Simcere Pharmaceutical’s First-half Earnings; Company “Very Close” To First Round Of Acquistions
BEIJING - The massive 7.9 magnitude earthquake that ripped through southwestern China three months ago also cut into Simcere Pharmaceutical's earnings for the first half of 2008, according to senior management at the Nanjing-based company
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).